Compare APT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | SCYX |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | Canada | United States |
| Employees | N/A | 29 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 44.0M |
| IPO Year | 1997 | 2014 |
| Metric | APT | SCYX |
|---|---|---|
| Price | $5.59 | $4.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 55.3K | ★ 77.8K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $59,142,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | $78.57 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $4.34 | $0.57 |
| 52 Week High | $7.50 | $5.62 |
| Indicator | APT | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 68.94 |
| Support Level | $5.49 | $0.67 |
| Resistance Level | $5.64 | $5.62 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 61.97 | 70.75 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.